BRCA1 and Lynch syndrome 2: Dosing this panel of antigens (OVALife test) provides a reliable screen of patients at high risk, such as women younger than 50 years old with positive familiarity for ovarian or breast cancer, particularly if they bear a BRCA1 or BRCA2 gene mutation or belong to families with Lynch 2 syndrome [23].